Non-small Cell Lung Cancer
Conditions
Keywords
TH-302, TH-CR-415, Pemetrexed, Non-small cell lung cancer, Lung cancer, Evofosfamide
Brief summary
The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
Detailed description
TH-302 is designed to target the hypoxic regions of tumors which are generally located distant from tumor vessels. Pemetrexed has poor tissue penetration and targets the regions of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic microenvironment. There is evidence supporting the presence of hypoxia in NSCLC lesions based on a hypoxia PET study. Combining pemetrexed with TH-302 may enable the targeting of both the normoxic and hypoxic regions of NSCLC lesions.
Interventions
DRUGTH-302 combination with pemetrexed
400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle. Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration.
DRUGMatched placebo in combination with pemetrexed
Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle. Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration.
Sponsors
EMD Serono
ImmunoGenesis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women ≥ 18 years of age. * Histologically or cytologically confirmed stage IIIB or IV NSCLC with non-squamous histology * Recurrent or progressive disease after one prior platinum-based non-pemetrexed chemotherapy treatment for advanced disease with or without maintenance * Neoadjuvant/adjuvant cytotoxic chemotherapy initiated \< 12 months prior to study randomization will be counted as one prior treatment * Neoadjuvant/adjuvant cytotoxic chemotherapy initiated ≥ 12 months prior to study randomization will not be counted as one prior chemotherapy treatment * Use of targeted agents (e.g., monoclonal antibodies or kinase inhibitors) will not be counted as a prior chemotherapy treatment * Patients with known EGFR-activating mutations or ALK rearrangements should have received treatment with a targeted kinase inhibitor (e.g., erlotinib, crizotinib) and no longer be considered as a candidate for such treatment * Measurable disease according to RECIST 1.1 * ECOG performance status 0-1 * Resolution to Grade ≤ 1 Adverse Events, of all clinically significant toxic effects of prior therapy * Adequate hematologic, hepatic, cardiac, and renal function * Female patients of childbearing potential must have a negative serum or urine pregnancy test, whichever is considered standard by the institution
Exclusion criteria
* Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung or NSCLC NOS * Prior therapy with pemetrexed * Inability or unwillingness to take folic acid, vitamin B12 supplementation or corticosteroids * Inability to discontinue non-steroidal anti-inflammatory drugs for 5 days (long half-life) or for 2 days (short half-life, if CrCL \<80 mL/min) before pemetrexed dosing and until 2 days after pemetrexed dosing * Leptomeningeal disease or any untreated or symptomatic brain metastases, unless the following criteria are met: * brain metastases are stable and have been previously treated with either whole-brain radiotherapy or gamma-knife surgery * steroids are currently not required and more than 14 days since last steroid treatment * Symptomatic pleural effusion (\> CTCAE Grade 1 dyspnea) that is not amenable to drainage * Treatment with other systemic anticancer therapy within 4 weeks prior to the first dose of study medication * Treatment with full field radiation therapy within 4 weeks or limited field radiation therapy within 2 weeks prior to the first dose of study medication * Major surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of study medication * Elective or a planned major surgery while on study treatment * Radiation therapy to greater than 25% of the bone marrow * Clinically significant active infection (e.g. tuberculosis, viral hepatitis, HIV) * Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct * Concurrent active malignancy other than adequately treated basal cell or squamous cell carcinoma of the skin or pre-invasive carcinoma of the cervix. * Pregnant or breast feeding * Patients who are taking medications that prolong QT interval and have a risk of Torsades de Pointes (Appendix F) or who have a history of long QT syndrome * Patients who are taking medications that are strong inducers or inhibitors of CYP3A4
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 2 years | To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo |
Countries
Czechia, Germany, Greece, Hungary, Italy, Poland, Romania, Russia, Spain, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TH-302 and Pemetrexed TH-302 in combination with pemetrexed
TH-302 combination with pemetrexed: 400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration. | 134 |
| Placebo and Pemetrexed Matching placebo in combination with pemetrexed
Matched placebo in combination with pemetrexed: Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration. | 131 |
| Total | 265 |
Baseline characteristics
| Characteristic | TH-302 and Pemetrexed | Placebo and Pemetrexed | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 53 Participants | 46 Participants | 99 Participants |
| Age, Categorical Between 18 and 65 years | 81 Participants | 85 Participants | 166 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 3 Participants | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 130 Participants | 126 Participants | 256 Participants |
| Sex: Female, Male Female | 58 Participants | 57 Participants | 115 Participants |
| Sex: Female, Male Male | 76 Participants | 74 Participants | 150 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 130 / 130 | 130 / 130 |
| serious Total, serious adverse events | 52 / 130 | 72 / 130 |
Outcome results
Primary
Overall Survival
To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo
Time frame: 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TH-302 and Pemetrexed | Overall Survival | 51 Participants |
| Placebo and Pemetrexed | Overall Survival | 49 Participants |